PARPar Drugs And Chemicals Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
| Bollinger Squeeze | LONG | 30% | ₹102.57 | ₹92.69 | ₹122.32 | 2.00 |
Why avoid
- • Risk gate: safety score is only 26/100 — volatility, drawdown or liquidity is too poor for a buy call, whatever the chart says
- • Revenue growth: -12.2% YoY
- • Profit growth: -48.5% YoY
- • Golden cross setup: SMA50 below SMA200
- • Volume: 0.8x 20-day average
⚖️ 1 bullish pattern setup is currently active on this stock. Pattern setup-quality percentages measure how cleanly a chart formation developed — they are not an endorsement of the company. Short-term traders may still trade those setups with strict stops; the AVOID verdict reflects the overall risk/fundamental profile for holding.
Bull case
- • Debt/Equity: 0.00
- • Valuation vs sector: P/E 9.9 vs sector 38.6
- • RSI: 62
- • MACD: fresh bullish crossover
Bear case
- • Revenue growth: -12.2% YoY
- • Profit growth: -48.5% YoY
- • Golden cross setup: SMA50 below SMA200
- • Volume: 0.8x 20-day average
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Revenue growth: -12.2% YoY
- • Profit growth: -48.5% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹5.93). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.